CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Cash and Short Term Investments

Last Annual Value

38.92M

3-Year CAGR

1%

5-Year CAGR

22%

10-Year CAGR

6%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of Cash and Short Term Investments

CRVO · NASDAQ
CompanyCash and Short Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
38.92M
70.9%0.8%38.0% 
7.80M
19.3%-22.3%N/A
79.38M
-0.6%-23.6%-1.4%
5.53M
421.7%132.9%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
158.53M
-0.2%-10.6%8.9%
CLNN logo
Clene Inc.
NASDAQ:CLNN
5.19M
-47.1%-36.5%N/A
57.95M
-24.4%-18.1%N/A
10.66M
8.8%-23.9%34.4%
100.41M
79.0%41.6%N/A
112.94M
-17.8%-17.6%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
63.81M
17.1%-17.5%5.2%
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5